United Therapeutics (UTHR) Income from Continuing Operations (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Income from Continuing Operations data on file, last reported at 274900000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 14.68% year-over-year to 274900000.0; the trailing twelve-month figure through Mar 2026 stood at 1287400000.0 (up 6.34% YoY), and the FY2025 full-year result was 1334700000.0, up 11.68% from the prior year.
• Income from Continuing Operations slipped to 274900000.0 in Q1 2026, from 364300000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 364300000.0 in Q4 2025 to a low of 116000000.0 in Q2 2022.
• A 5-year average of 265694117.65 and a median of 274900000.0 in 2026 frame the typical range for Income from Continuing Operations.
• Peak annual rise in Income from Continuing Operations reached 747.7% in 2022, while the deepest fall reached 32.79% in 2022.
• Tracing UTHR's Income from Continuing Operations over 5 years: stood at 132100000.0 in 2022, then surged by 64.35% to 217100000.0 in 2023, then surged by 38.78% to 301300000.0 in 2024, then increased by 20.91% to 364300000.0 in 2025, then retreated by 24.54% to 274900000.0 in 2026.
• Business Quant data shows UTHR's Income from Continuing Operations at 274900000.0 in Q1 2026, 364300000.0 in Q4 2025, and 338700000.0 in Q3 2025.